Cantor Fitzgerald Has Weak Forecast for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Beam Therapeutics in a report issued on Wednesday, November 5th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($4.45) per share for the year, down from their prior forecast of ($4.42). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Cantor Fitzgerald also issued estimates for Beam Therapeutics’ FY2026 earnings at ($4.18) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). Beam Therapeutics had a negative return on equity of 42.86% and a negative net margin of 744.41%.The business had revenue of $9.70 million for the quarter, compared to analyst estimates of $12.83 million. During the same period in the previous year, the business posted ($1.17) EPS. The business’s quarterly revenue was down 32.2% compared to the same quarter last year.

Several other brokerages also recently commented on BEAM. JPMorgan Chase & Co. dropped their target price on shares of Beam Therapeutics from $48.00 to $46.00 and set an “overweight” rating on the stock in a report on Thursday, October 9th. Wall Street Zen raised shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Barclays dropped their price target on Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a report on Friday, October 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Beam Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $46.55.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $23.15 on Friday. Beam Therapeutics has a one year low of $13.52 and a one year high of $35.25. The firm has a market cap of $2.35 billion, a P/E ratio of -5.23 and a beta of 2.40. The stock’s 50-day moving average is $23.87 and its 200-day moving average is $20.23.

Institutional Investors Weigh In On Beam Therapeutics

Large investors have recently made changes to their positions in the stock. Allworth Financial LP increased its holdings in Beam Therapeutics by 7,080.0% during the second quarter. Allworth Financial LP now owns 2,513 shares of the company’s stock worth $43,000 after buying an additional 2,478 shares during the last quarter. CWM LLC lifted its stake in Beam Therapeutics by 79.8% in the 1st quarter. CWM LLC now owns 2,684 shares of the company’s stock valued at $52,000 after purchasing an additional 1,191 shares during the last quarter. Amalgamated Bank lifted its stake in Beam Therapeutics by 20.4% in the 1st quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock valued at $62,000 after purchasing an additional 534 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in Beam Therapeutics by 1,248.8% during the second quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company’s stock worth $65,000 after purchasing an additional 3,534 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Beam Therapeutics by 43.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company’s stock valued at $66,000 after buying an additional 1,175 shares during the period. Institutional investors and hedge funds own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.